SEC Form 4 · accession 0001209191-18-041189
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — CEO · Director
Period of report
Jun 28, 2018
Accepted (ET)
Jul 3, 2018 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 28, 2018 | M | 124,804 | $4.04 | A | 1,549,959 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.04 | Jun 28, 2018 | M | 124,804 | D | — | Apr 2, 2019 | Common Stock | 124,804 | 0 | D |
Explanation of responses
- F125% of the shares subject to the option vested on April 2, 2010 and the remainder vested in equal monthly installments over a period of three years ending April 2, 2013.